Trastuzumab (Herceptin), an inhibitor of HER2, has been proven to target HER2-expressing BCSCs and inhibit the tumor growth of patient-derived xenografts from HER2-negative breast cancer [126]. The gene discussed is ERBB2; the disease is neoplasm.